StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.61+0.01 (+0.63%)

Close on Nov 18, 2026Market cap $80.25MP/E –Yield –

Polaryx Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Polaryx Therapeutics

Polaryx Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Polaryx Therapeutics figures

See a number that looks wrong?